SPECIAL REPORT: GLP-1s and the FDA Personalized Compounding Exemption Why Hims is on solid legal ground to continue selling GLP-1s even after the shortage is over This report is about why Hims is on solid legal ground to continue selling GLP-1s even after the semaglutide shortage ends
What's the difference between Wegovy and other GLP-1 medications
There is no conclusive evidence for pancreatic cancer from clinical trials, but it is still considered a potential risk, particularly in patients with type 2 diabetes
Nausea, constipation, or diarrhea, loss of appetite/feeling of fullness and acid reflux
A recent meta-analysis of RCTs reported improvements in several metabolic parameters, including markers of glycemic control, insulin sensitivity, and lipid metabolism, demonstrating that targeted modulation of the gut ecosystem can shift clinically relevant endpoints in humans (140)
Use high-quality raw materials